– Presentations include early data from
– Encore presentation of data from CRB-401 study of bb2121 in relapsed/refractory multiple myeloma to be presented –
“This year at EHA, we will share the first clinical data from our
HGB-207 study of LentiGlobin in patients with TDT and non-β0/β0
genotypes, using our refined drug product manufacturing process,” said
Oral Presentations
A Phase 3
Study to Evaluate Safety and Efficacy of LentiGlobin Gene Therapy for
Transfusion-Dependent β-thalassemia in Patients with non-β0/β0
Genotypes: The
Presenter:
Date & Time:
Location:
First-in-Human Multicenter Study of bb2121 anti-BCMA CAR T Cell Therapy for Relapsed/Refractory Multiple Myeloma: Updated Results. (Abstract S142)
Presenter:
Date & Time:
Location:
Note: This will be an encore of data presented at the
Poster Presentation
Update
on the First Patients with Severe Hemoglobinopathies Treated with
LentiGlobin Gene Therapy (HGB-205) (Abstract P631)
Presenter: TBD
Poster Session Date & Time:
Location: Poster
area (Hall 7)
About bluebird bio, Inc.
With its lentiviral-based gene
therapies, T cell immunotherapy expertise and gene editing capabilities,
bluebird bio has built an integrated product platform with broad
potential application to severe genetic diseases and cancer. bluebird
bio’s gene therapy clinical programs include its Lenti-D™ product
candidate, currently in a Phase 2/3 study, called the Starbeam Study,
for the treatment of cerebral adrenoleukodystrophy, and its LentiGlobin™
product candidate, currently in four clinical studies for the treatment
of transfusion-dependent β-thalassemia, and severe sickle cell disease.
bluebird bio’s oncology pipeline is built upon the company’s leadership
in lentiviral gene delivery and T cell engineering, with a focus on
developing novel T cell-based immunotherapies, including chimeric
antigen receptor (CAR T) and T cell receptor (TCR) therapies. bluebird
bio’s lead oncology program, bb2121, is an anti-BCMA CAR T program
partnered with Celgene. bb2121 is currently being studied in a Phase 1
trial for the treatment of relapsed/refractory multiple myeloma.
bluebird bio also has discovery research programs utilizing
megaTAL/homing endonuclease gene editing technologies with the potential
for use across the company’s pipeline.
bluebird bio has operations in Cambridge, Massachusetts, Seattle,
Forward-Looking Statements
This release contains
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements regarding
the Company’s research, development, manufacturing and regulatory
approval plans for its LentiGlobin product candidate to treat
transfusion-dependent ß-thalassemia and severe sickle cell disease and
its bb2121 product candidate to treat relapsed/refractory multiple
myeloma, including statements whether the manufacturing process changes
for LentiGlobin will improve outcomes of patients with
transfusion-dependent ß-thalassemia and severe sickle cell disease,
whether the planned changes to the HGB-206 clinical trial protocol will
improve outcomes in patients with severe sickle cell disease. Any
forward-looking statements are based on management’s current
expectations of future events and are subject to a number of risks and
uncertainties that could cause actual results to differ materially and
adversely from those set forth in or implied by such forward-looking
statements. These risks and uncertainties include, but are not limited
to, the risks that the preliminary positive efficacy and safety results
from our prior and ongoing clinical trials of LentiGlobin will not
continue or be repeated in our ongoing, planned or expanded clinical
trials of LentiGlobin, the risks that the changes we have made in the
LentiGlobin manufacturing process or the HGB-206 clinical trial protocol
will not result in improved patient outcomes, risks that the current or
planned clinical trials of LentiGlobin will be insufficient to support
regulatory submissions or marketing approval in the US and EU, the risk
of a delay in the enrollment of patients in our clinical studies, and
the risk that any one or more of our product candidates, including our
bb2121 product candidate, will not be successfully developed, approved
or commercialized. For a discussion of other risks and uncertainties,
and other important factors, any of which could cause our actual results
to differ from those contained in the forward-looking statements, see
the section entitled “Risk Factors” in our most recent Form 10-Q, as
well as discussions of potential risks, uncertainties, and other
important factors in our subsequent filings with the
View source version on businesswire.com: http://www.businesswire.com/news/home/20170518005534/en/
Source: bluebird bio, Inc.
bluebird bio, Inc.
Investors:
Manisha Pai, 617-245-2107
mpai@bluebirdbio.com
or
Media:
Elizabeth
Pingpank, 617-914-8736
epingpank@bluebirdbio.com